Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data Apoe, Ogheneruona , Jung, Sin-Ho , Liu, Heshan , Seisler, Drew K ... - - Am J Hematol Oncol - 2016 Manuscript - Primary - Preliminary - Prevention - CALGB-70806
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303 Bartlett, Nancy L. , Wilson, Wyndham H. , Jung, Sin-Ho , Hsi, Eric D. ... - - J. Clin. Oncol - 2019 Manuscript - Primary - Primary - Lymphoma - CALGB-50303
Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance) Blum, Kristie A. , Jung, Sin-Ho , Barak, Ian , Hsi, Eric D. ... - ASH - Blood - 2017 Abstract - Primary - Primary - Lymphoma - CALGB-50904
Randomized Trial of Ofatumumab and Bendamustine versus Ofatumumab, Bendamustine and Bortezomib in previously untreated patients with highrisk follicular lymphoma: CALGB 50904 (Alliance) Blum, Kristie A. , Polley, Mei-Yin , Jung, Sin-Ho ... - - Cancer - 2019 Manuscript - Primary - Primary - Lymphoma - CALGB-50904
CALGB 150905 (Alliance): Rituximab broadens the anti-lymphoma response by activating unlicensed NK cells Du, Juan , Lopez-Verges, Sandra , Pitcher, Brandelyn N. ... - - Cancer Immunol Res - 2014 Manuscript - Primary - Primary - Lymphoma - CALGB-150905 , CALGB-50402 , CALGB-50701
Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance) Fulton, Noreen , Johnson, Jeffrey , Kaplan, Lawrence D. , Koval, Greg ... - ASH - Blood - 2013 Abstract - Secondary - Primary - Lymphoma - CALGB-50403
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254 Furman, Richard R. , Grossbard, Michael L. , Johnson, Jeffrey L. ... - - Leuk. Lymphoma - 2011 Manuscript - Primary - Primary - Lymphoma - CALGB-9254
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Grant, Barbara W , Jung, Sin-Ho , Johnson, Jeffrey L ... - - Cancer - 2013 Manuscript - Primary - Primary - Lymphoma - CALGB-50701
Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma Holstein, Sarah A. , Jung, Sin-Ho , Richardson, Paul G. ... - - Lancet Haematol - 2017 Manuscript - Primary - Long-Term-Followup - Myeloma - CALGB-100104
Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study Hsi, Eric D. , Jung, Sin-Ho , Lai, Raymond , Johnson, Jeffrey L. ... - - Leuk. Lymphoma - 2008 Manuscript - Secondary-not-in-original - Primary - Lymphoma - CALGB-59909
Bortezomib Maintenance (Bm) Versus Consolidation (Bc) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (Asct) For Untreated Mantle Cell Lymphoma (Mcl): CALGB 50403 Kaplan, Lawrence D. , Stock, Wendy , Jung, Sin-Ho , Bartlett, Nancy ... - ASH - Blood - 2015 Abstract - Primary - Primary - Lymphoma - CALGB-50403
Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Kostakoglu, Lale , Schöder, Heiko , Johnson, Jeffrey L ... - - Leuk. Lymphoma - 2012 Manuscript - Secondary - Primary - Lymphoma - CALGB-50203
High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. Lai, Raymond , Bartlett, Nancy L , Mackey, John R , Jung, Sin-Ho ... - - Leuk. Lymphoma - 2008 Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-59804
Early relapse of follicular lymphoma after rituximab-based biologic doublet upfront therapy is associated with increased risk of death: a combined analysis from CALGB/Alliance Studies 50402, 50701 and 50803 Lansigan, Frederick , Barak, Ian , Pitcher, Brandelyn , Jung, Sin-Ho ... - ASH - Blood - 2016 Abstract - Secondary-not-in-original - Meta-Analysis - Lymphoma - CALGB-50402 , CALGB-50701 , CALGB-50803
Comparison of results from three different density assessment methods on mammographic density (MD) in a screening patients receiving vitamin D (Vit D): Results of CALGB 70806 (Alliance) Le-Petross, Huong T. , Seisler, Drew K. , Kontos, Despina ... - RSNA - - 2018 Abstract - Secondary - Primary - Prevention - CALGB-70806
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance) Leonard, John P. , Jung, Sin-Ho , Johnson, Jeffrey ... - - J. Clin. Oncol - 2015 Manuscript - Primary - Primary - Lymphoma - CALGB-50401
Alliance A051202: A Phase I Trial of Lenalidomide, Rituximab and GS-1101 (Idelalisib) in recurrent follicular lymphoma Leonard, John P. , Jung, Sin-ho ... - ICML - Hematol Oncol - 2013 Abstract - No-Endpoint - Trial-Description-Only - Lymphoma - A051202
CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma Martin, Peter , Jung, Sin-Ho , Johnson, Jeffrey L. , Pitcher, Brandy ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary - Primary - Lymphoma - CALGB-50803
Final results of CALGB 50803 (Alliance): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma Martin, Peter , Jung, Sin-Ho , Pitcher, Brandy , Bartlett, Nancy ... - ICML - Hemato Oncol - 2017 Abstract - Primary - Long-Term-Followup - Lymphoma - CALGB-50803
Lenalidomide vs Placebo Maintenance After Stem Cell Transplant for Patients With Multiple Myeloma: Overall Survival and Progression-Free Survival After Adjusting for Treatment Crossover in CALGB McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - EHA - Haematologica - 2017 Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
CALGB/ECOG 100104 (Alliance) Study: Lenalidomide (LEN) vs Placebo (PBO) Maintenance (Maint) After Stem Cell Transplant (SCT) for Patients (Pts) With Multiple Myeloma: Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment (Tx) Crossover (XO) McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
Overall and Progression-Free Survival Adjusted for Treatment Crossover in the CALGB 100104 Study of Lenalidomide Versus Placebo Maintenance After Stem Cell Transplant for Patients With Newly Diagnosed Multiple Myeloma (Alliance) McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - IMW - - 2017 Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis McCarthy, Philip L. , Holstein, Sarah A. , Petrucci, Maria Teresa ... - - J. Clin. Oncol - 2017 Manuscript - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501) Morrison, Vicki A. , Jung, Sin-Ho , Johnson, Jeffrey , LaCasce, Ann ... - - Leuk. Lymphoma - 2015 Manuscript - Primary - Primary - Lymphoma - CALGB-50501
A Randomized Trial of Diet in Men with Early Stage Prostate Cancer on Active Surveillance: Rationale and Design of the Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance]) Parsons, J. Kellogg , Pierce, John P. , Mohler, James ... - - Contemp Clin Trials - 2014 Manuscript - No-Endpoint - Trial-Description-Only - Prevention - CALGB-70807
The Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): Recruitment Feasibility and Baseline Demographics of a Randomized Trial of Diet in Men on Active Surveillance for Prostate Cancer Parsons, J. Kellogg , Pierce, John P. , Mohler, James ... - - BJU Int. - 2018 Manuscript - Secondary-not-in-original - Preliminary - Prevention - CALGB-70807
Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance) Rosenbaum, Cara A. , Pitcher, Brandelyn , Bartlett, Nancy L ... - ASH - Blood - 2015 Abstract - Primary - Primary - Lymphoma - CALGB-50901
Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). Rosenbaum, Cara A , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Br. J. Haematol. - 2019 Manuscript - Primary - Primary - Lymphoma - CALGB-50901
High proliferation by the MCL35 assay is associated with inferior outcomes in patients treated with intensive regimens – a correlative study from the Alliance 50403 trial. Scott, David W. , Pitcher, Brandelyn , Liu, Yi Tian , Boyle, Merrill ... - ICML - Hematol Oncol - 2017 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-50403
Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: Alliance A051201 and A051202 Smith, Sonali M. , Pitcher, Brandelyn N. , Jung, Sin-Ho ... - ASH - Blood - 2014 Abstract - Secondary - Meta-Analysis - Lymphoma - A051201 , A051202
Safety and Tolerability of Idelalisib, Lenalidomide, and Rituximab in Relapsed and Refractory Lymphoma: Alliance A051201 and A051202 Phase I Trials Smith, Sonali M. , Pitcher, Brandelyn N. , Jung, Sin-Ho ... - - Lancet Haematol - 2017 Manuscript - Primary - Primary - Lymphoma - A051201 , A051202
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance) Smith, Sonali M. , Schöder, Heiko , Johnson, Jeffrey L. ... - - Leuk. Lymphoma - 2013 Manuscript - Primary - Primary - Lymphoma - CALGB-50602
Biomarkers for Risk Stratification in Patients with Previously Untreated Follicular Lymphoma Receiving Anti-CD20-Based Biologic Therapy Sohani, Aliyah R. , Maurer, Matthew J. , Giri, Sharmila ... - - Am J Surg Pathol - 2021 Manuscript - Secondary-not-in-original - Meta-Analysis - Correl Sci NOS - CALGB-50402 , CALGB-50701 , CALGB-50803 , CALGB-50901
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET Straus, David J. , Johnson, Jeffrey L. , LaCasce, Ann S. ... - - Blood - 2011 Manuscript - Primary - Primary - Lymphoma - CALGB-50203
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET Straus, David J. , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Blood - 2018 Manuscript - Primary - Primary - Lymphoma - CALGB-50604
Results of US Intergroup Trial of Response-Adapted Chemotherapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604) Straus, David J. , Pitcher, Brandelyn N. , Kostakoglu, Lale ... - ASH - Blood - 2015 Abstract - Primary - Preliminary - Lymphoma - CALGB-50604
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611)☆ Tallarico, Michael , Foster, Jared C. , Seisler, Drew ... - - J Geriatr Oncol - 2018 Manuscript - Secondary - Primary - Older Adult - A151611
Beyond maximum grade: A novel, longitudinal toxicity over time (ToxT) adverse event analysis of lenalidomide in follicular lymphoma in Alliance A151617 Thanarajasingam, Gita , Dueck, Amylou , Novotny, Paul J. ... - ICML - Hematol Oncol - 2017 Abstract - Primary - Primary - Health Outcome - CALGB-50401 , A151617
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in CALGB 50401 (Alliance) Thanarajasingam, Gita , Leonard, John P. , Witzig, Thomas E. ... - - Lancet Haematol - 2020 Manuscript - No-Endpoint - Other - Health Outcome - A151617 , CALGB-50401
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103 Ujjani, Chaitra S. , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Blood - 2016 Manuscript - Primary - Primary - Lymphoma - A051103
Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103) Ujjani, Chaitra , Jung, Sin-Ho , Pitcher, Brandelyn , Martin, Peter ... - ASH - Blood - 2015 Abstract - Primary - Primary - Lymphoma - A051103
Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: Alliance/CALGB 50303 Wilson, Wyndham H. , Jung, Sin-Ho , Pitcher, Brandelyn , Hsi, Eric ... - ASH - Blood - 2016 Abstract - Primary - Primary - Lymphoma - CALGB-50303
The influence of vitamin D on mammographic density: results from CALGB 70806 (Alliance) Wood, Marie , Liu, Heshan , Storrick, Elizabeth , Zahrieh, David ... - - Cancer Prev Res (Phila) - 2021 Manuscript - Primary - Primary - Prevention - CALGB-70806
Influence of vitamin D (Vit D) on mammographic density (MD) and insulin like growth factor 1 (IGF1): results of CALGB (Alliance) 70806 Wood, Marie , Seisler, Drew K. , Hsieh, Meng-Kang , Kontos, Despina ... - ASCO - J. Clin. Oncol. - 2018 Abstract - Primary - Primary - Prevention - CALGB-70806
